In this issue of Digestive and Liver Disease, ITA.LI.CA. a large, well-known, efficient
and productive Italian cooperative group devoted to the study of liver cancer analyzed
the theoretical eligibility for the combination of atezolizumab plus bevacizumab among
their patients with advanced HCC who received at least one dose of systemic therapy
with a tyrosin kinase inhibitor (TKI) [
[1]
]. Eligibility was assessed according to the criteria adopted for the IMBRAVE 150
phase 3 registration trial [
[2]
] and was found to reach hardly 30% of all patients.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Digestive and Liver DiseaseAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- for the Italian Liver Cancer (ITA.LI.CA) group. Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors.Dig Liv Dis. 2022; 54: 1563-1572https://doi.org/10.1016/j.dld.2022.07.003
- Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.N Engl J Med. 2020; 382: 1894-1905https://doi.org/10.1056/NEJMoa1915745
- Observational registry of sorafenib use in clinical practice across child-pugh subgroups: the GIDEON study.J Hepatol. 2016; 65: 1140-1147https://doi.org/10.1016/j.jhep.2016.07.020
- A multicenter, observational, phase 4 study (STELLAR) to evaluate the safety and tolerability of Lenvatinib (LEN) in patients with advanced or unresectable hepatocellular carcinoma (uHCC).J Clin Oncol. 2022; 40 (-TPS485): TPS485
- Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy.Hepatology. 2011; 54: 2055-2063https://doi.org/10.1002/hep.24644
- Real-life clinical data of lenvatinib versus sorafenib for unresectable hepatocellular carcinoma in Italy.Cancer Manag Res. 2021; 24: 9379-9389https://doi.org/10.2147/CMAR.S330195
- Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study.Hepatology. 2022; (Published online March 21)https://doi.org/10.1002/hep.32468
- Sorafenib in advanced hepatocellular carcinoma.N Engl J Med. 2008; 359: 378-390https://doi.org/10.1056/NEJMoa0708857
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.Lancet. 2018; 24 (10126): 1163-1173
- Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.NEJM Evid. 2022; 1https://doi.org/10.1056/EVIDoa2100070
- Sorafenib as first-line therapy in patients with advanced child-pugh B hepatocellular carcinoma-a meta-analysis.Eur J Cancer. 2018; 105: 1-9https://doi.org/10.1016/j.ejca.2018.09.031
- Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses.J Hepatol. 2012; 56: 1080-1088https://doi.org/10.1016/j.jhep.2011.12.009
- Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma.Dig Liver Dis. 2022; 27 (S1590-8658(22)00205-5)https://doi.org/10.1016/j.dld.2022.03.002
- Optimising systemic therapy for advanced hepatocellular carcinoma: the key role of liver function.Dig Liver Dis. 2022; 54: 452-460https://doi.org/10.1016/j.dld.2022.01.122
- The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma.J Hepatol. 2022; 76: 1185-1198https://doi.org/10.1016/j.jhep.2021.11.013
Article info
Publication history
Published online: September 17, 2022
Accepted:
August 24,
2022
Received:
August 19,
2022
Identification
Copyright
© 2022 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitorsDigestive and Liver DiseaseVol. 54Issue 11
